NCT02725957View on ClinicalTrials.gov

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy Volunteer Subjects
Interventions
DRUG

Trehalose for IV Infusion

DRUG

Saline 0.9% IV

Trial Locations (1)

21225

PAREXEL Baltimore Early Phase Clinical Unit; Harbor Hospital, Baltimore

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Bioblast Pharma Ltd.

INDUSTRY